Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872847 | 1.00 | PPARD (0.42) | PPARDPPARGPPARAFFAR1MAPT | |
| SCHEMBL1869256 | 0.83 | FFAR1 (0.50) | PPARDPPARGPPARAFFAR1MAPT | |
| SCHEMBL1872814 | 0.80 | PPARA (0.58) | PPARGPPARAMAPTALDH1A1 | |
| SCHEMBL1862898 | 0.78 | FFAR1 (0.43) | PPARDPPARGPPARAFFAR1MAPT | |
| SCHEMBL12803179 | 0.76 | PPARD (0.48) | PPARDPPARGPPARAFFAR1NPC1 | |
| SCHEMBL4246301 | 0.74 | PPARD (0.66) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL4254697 | 0.74 | PPARD (0.66) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL4246297 | 0.74 | PPARD (0.66) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL4246080 | 0.73 | PPARD (0.61) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL4247774 | 0.73 | PPARD (0.61) | PPARDPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | disclosed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | PCSK9, APOB, CPT1A | PPARD 127/4885PPARG 122/4885PPARA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.